The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can and or wants to take them. In this episode, which is based on Goldman Sachs Research’s latest Top of Mind report, obesity medicine physician Dr. Fatima Cody Stanford and Jonathan Gruber, professor of economics and chairman of the Economics Department at MIT, discuss how large the addressable market for GLP-1s actually is and the implications for US fiscal health.
If you want more insights from Goldman Sachs, make sure to visit GS.com and sign up for Briefings, a weekly newsletter from Goldman Sachs about trends spanning markets, industries, and the global economy.
The Markets: Why European stocks are beating US equities
Investing during times of market stress
The Markets: Pricing in the probability of a recession
Breaking Free: The rise of corporate separations
U.S.-China: more decoupling ahead?
The Markets: Fed rate hikes, banking stress & debt limit concerns
Is big tech back?
What happens if the U.S. government can’t pay its bills?
The Markets: Volatility, Earnings, and European Equities
Navigating the trillion dollar path to a more sustainable economy
How Porsche CEO Oliver Blume is driving innovation
The Markets: A ‘bulletproof’ stock market?
Navigating the ‘perfect storm’ in commercial real estate
What’s on the minds of the world’s largest investors?
All about bank(panic)s and the implications for policy
How Europe’s tech startups are continuing to innovate in the current market
What’s driving the surge in shareholder activism activity?
Bain Capital’s Stephen Pagliuca on private equity and the Boston Celtics
Navigating the new geopolitical and technology landscape
What the banking turmoil means for investors’ portfolios
Create your
podcast in
minutes
It is Free
The Business Of
TED Radio Hour
FT Alphachat
Freakonomics Radio
Odd Lots
Slate Money